Do Antioxidants Prevent Altitude Sickness? The RCT Verdict

Antioxidants have a sensible biochemical case for preventing acute mountain sickness (AMS). They do not yet have a convincing clinical case. A 2026 meta-analysis found that antioxidant treatment was associated with a relative risk of 0.73 for AMS versus placebo—a 27% directional reduction—but the result was not statistically significant. For a trekker deciding what to pack, that means vitamins C and E, alpha-lipoic acid, and Ginkgo biloba remain unproven adjuncts, not substitutes for acclimatization or established prevention.

The distinction matters at altitude. AMS can make a climb miserable; severe altitude illness can become dangerous. A supplement that truly cut AMS incidence by 27% would be useful, especially where AMS is common above 3,500 meters. But a promising point estimate from a small, mixed evidence base is a reason to run better trials, not a reason to retire caution.

Why the antioxidant idea makes biological sense

Hypobaric hypoxia—the lower oxygen pressure at altitude—raises oxidative-stress markers quickly. A 2023 review by Peña et al. describes increases in reactive oxygen species, malondialdehyde (MDA), and hydrogen peroxide during altitude exposure. In studies summarized by that review, MDA and hydrogen peroxide in exhaled breath condensate rose at rest and during exercise, tracked with worse Lake Louise Scores, and varied inversely with oxygen saturation.

Those findings fit a plausible sequence: reduced oxygen availability disrupts cellular metabolism, reactive oxygen species rise, and oxidative injury may contribute to the vascular and inflammatory changes involved in altitude illness. Animal lung studies reviewed by Peña et al. detected increased reactive oxygen species and MDA within 1.5 hours of acute hypobaric hypoxia, earlier than the usual 6-to-12-hour window for AMS symptoms. That timing explains the appeal of taking antioxidants before ascent.

Plausibility, however, is not proof of prevention. Biomarkers can identify a pathway without proving that changing the pathway prevents headaches, nausea, dizziness, fatigue, or other AMS symptoms. Human biology has a talent for making a tidy pathway diagram look optimistic.

Oxidative stress also sits inside a larger response. A 2026 review by Zhang et al. describes hypoxia-related immune dysregulation, inflammatory signaling, neutrophil activity, and endothelial damage across AMS, high-altitude pulmonary edema, and high-altitude cerebral edema. Antioxidants might affect one part of that cascade, but the review does not establish that antioxidant supplements alone prevent those illnesses.

What the randomized evidence actually found

The strongest direct evidence comes from a 2026 systematic review and meta-analysis by Peña et al. The review identified 19 studies of antioxidant interventions for altitude-induced AMS. These interventions included vitamins C and E, alpha-lipoic acid, and standardized Ginkgo biloba extract.

Only four studies provided the placebo-controlled, dichotomous AMS-incidence data needed for quantitative pooling. Using a random-effects model, the authors calculated a pooled relative risk of 0.73 for AMS with antioxidants versus placebo. The estimate points toward fewer AMS cases in the antioxidant groups, but it did not reach statistical significance. The analysis therefore cannot rule out chance as an explanation for the observed difference.

The result is neither a clean failure nor a demonstrated benefit. Relative risk describes the proportional difference between groups, not the number of people helped. Without a reliable baseline AMS risk for a particular itinerary, it cannot yield an absolute risk reduction or a number needed to treat. A 27% relative reduction would matter clinically if confirmed; the present trials do not confirm it.

Why pooling does not identify a winning supplement

The pooled estimate combines different compounds, including vitamins C and E, alpha-lipoic acid, and Ginkgo biloba, across differing altitude exposures and ascent protocols. That approach can detect a broad class signal, but it cannot establish that each product works. The available analysis does not provide recoverable subgroup effect estimates for individual compounds, so it cannot support claims that one antioxidant has beaten placebo.

Ginkgo biloba deserves particular restraint. The underlying trial literature includes conflicting results, including studies cited in the review by Gertsch, Leadbetter, and Chow. The meta-analysis does not resolve those differences with a statistically persuasive Ginkgo-specific result. "Proven altitude protection" is too strong a label for Ginkgo based on these data.

The largest problem: most of the literature was uncontrolled

Fifteen of the 19 studies identified in the review lacked control groups. That is 79% of the literature examined. Before-and-after studies can show that symptoms or biomarkers changed over time, but they cannot reliably separate a supplement effect from acclimatization, prior altitude exposure, changes in ascent behavior, regression toward the mean, or placebo effects.

This is not a minor technical complaint. Altitude symptoms often change as people acclimatize, which makes uncontrolled improvement especially easy to misread. The four poolable trials deserve more weight than the larger uncontrolled remainder, even though four trials still leave substantial uncertainty.

Outcome definitions add another complication. The Lake Louise Score changed in 2018, removing mandatory headache from the AMS diagnosis. Studies using different versions can produce different incidence estimates even when participants feel similarly unwell. Peña et al. noted Lake Louise Score use across studies but did not specify which version each trial used. That uncertainty weakens direct comparison across trials and can reduce the precision of a pooled result.

Important practical details also remain unresolved across the evidence: dose, timing relative to ascent, pre-loading versus supplementation during exposure, altitude profile, and ascent rate. A low-dose vitamin trial and a higher-dose combination trial do not answer the same clinical question. Pooling them may be reasonable for exploration; it does not create a universal supplement protocol.

Related physiology is interesting, but it is not AMS prevention

Dietary compounds can change some altitude-related physiology without preventing AMS. A 2025 randomized, placebo-controlled crossover trial by Karl et al. tested food products containing fermentable fibers and polyphenol sources against maltodextrin placebo in healthy adults. Participants completed three two-week phases, and during the final 36 hours they stayed in a hypobaric chamber simulating either 500 or 4,300 meters. The supplement prevented hypobaric-hypoxia-related increases in intestinal permeability. That is a meaningful physiological endpoint, but it was not an AMS trial using Lake Louise Score incidence as its endpoint.

A separate high-altitude lesson comes from the Xtreme Alps nitrate trial. In 27 healthy volunteers assessed after five to eight days at 4,559 meters, beetroot juice supplying about 0.18 mmol nitrate per kilogram per day did not significantly improve exercise efficiency or reduce fatigue compared with nitrate-depleted placebo. Nitrate and antioxidants act through different proposed mechanisms, but both examples warn against converting mechanistic promise into a travel recommendation before outcomes trials support it.

What belongs in an altitude plan

For serious exposure—rapid ascent, elevations above 3,500 meters, or a previous history of AMS—gradual acclimatization should remain the foundation. Peña et al. describe acetazolamide as the established pharmacological preventive. It can cause paresthesia, altered taste, hyperglycemia, and rebound symptoms after discontinuation, so a clinician should help assess whether it fits an individual plan and medical history.

• Do not use antioxidant supplements as a replacement for a cautious ascent schedule.
• Do not treat vitamins C and E, alpha-lipoic acid, or Ginkgo biloba as proven AMS prevention.
• Consider any antioxidant regimen an unproven adjunct, not a substitute for acetazolamide when established prevention is appropriate.
• Seek medical advice before a high-risk ascent, especially after prior severe altitude illness or with relevant health conditions.

The current pooled estimate is interesting: relative risk 0.73, four poolable trials, and no statistical significance. It supports better, standardized trials; it does not yet justify a confident supplement recommendation.

The next useful studies would compare specific compounds and combinations at defined doses, standardize ascent profiles, use the current 2018 Lake Louise criteria, and report compound-level results. Until those data arrive, antioxidants are biologically plausible and clinically unsettled.